Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED NDA Acceptance in China for ORPATHYS® & TAGRISSO® Lung Cancer
Details : Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 01, 2025
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO®
Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fruquintinib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
Details : HMPL-013 (fruquintinib) is the first and only selective inhibitor of all three VEGF receptor kinases which is being evaluated for the treatment of gastroesophageal junction adenocarcinoma.
Product Name : Elunate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2024
Lead Product(s) : Fruquintinib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Launches RAPHAEL Phase III Trial of HMPL-306 for Acute Myeloid Leukemia
Details : HMPL-306 is a novel selective small molecule dual inhibitor of isocitrate dehydrogenase 1 and 2 mutations. It is being evaluated in the phase III for relapsed/refractory acute myeloid leukemia.
Product Name : HMPL-306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : Fruquintinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
Details : Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. NDA has been acceptance in china for fruquintinib in second-line gastric cancer.
Product Name : Elunate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2023
Lead Product(s) : Fruquintinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fruquintinib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.
Product Name : Elunate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Fruquintinib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Osimertinib Mesylate,Savolitinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary results from SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an ORR of 49% in patients with epidermal growth factor receptor-mutated NSCLC with high levels of mesenchymal epithelial transition overex...
Product Name : Tagrisso
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Osimertinib Mesylate,Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : $140.0 million
Deal Type : Collaboration
Details : This milestone has been triggered by the initiation of SAFFRON, the first global Phase III study for ORPATHYS in combination with TAGRISSO in EGFR - mutated non-small cell lung cancer patients with mesenchymal epithelial transition receptor driven tumors...
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 03, 2022
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : $140.0 million
Deal Type : Collaboration
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safety and efficacy of HMPL-012 (surufatinib), an oral inhibitor of angiogenesis and immune modulation, was demonstrated in SANET-p and SANET-ep studies, in patients with advanced pNETs and epNETs conducted in China.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) ...
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable